TipHub

2,543.7

+115.35 +4.75%

As of 27 Jul 2026 · delayed

NSE Listed

Gland Pharma Limited (GLAND)

Volume: 3,00,618Avg Vol 1W: 3,07,436.8Avg Vol 1M: 4,84,736.852W Range:1,573.62,573.5
Key Ratios
Checked 2d ago
Market Cap₹40,075 Cr
Current Price₹2,543.7
Previous Close₹2,428.35
High / Low (52w)₹2,573.5 / ₹1,573.6
Volume3,00,618
Avg Vol (1W)3,07,436.8
Avg Vol (1M)4,84,736.8
Stock P/E109.14
Book Value₹628.52
Dividend Yield0.9%
ROE9.9%
ROA8.2%
Revenue (TTM)₹5,830 Cr
Revenue Growth-0.8%
Profit Margin16%
Total Debt₹78 Cr
Shares Outstanding16 Cr
Face Value₹1
EPS (TTM)₹22.26
P/B3.87
Debt / Equity0.03
50 DMA₹2,359.47
200 DMA₹1,933.91
Day change+4.75%
Price Chart
2,543.7 23.44% · 1Y
2550159771.3L
2025-07-30
2026-07-27

20-day avg volume: 4.8L shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 23% YoY.
  • Stock trades at a high P/E of 109.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹1,402 Cr₹1,406 Cr₹1,384 Cr₹1,425 Cr₹1,506 Cr₹1,487 Cr₹1,695 Cr₹1,743 Cr
EBITDA₹224 Cr₹263 Cr₹322 Cr₹296 Cr₹324 Cr₹292 Cr₹390 Cr₹516 Cr
Net Profit₹144 Cr₹164 Cr₹205 Cr₹187 Cr₹215 Cr₹184 Cr₹261 Cr₹367 Cr
EPS
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹1,063 Cr₹1,011 Cr₹1,030 Cr₹5,830 Cr₹1,039 Cr₹1,074 Cr₹1,178 Cr₹1,262 Cr
EBITDA₹380 Cr₹412 Cr₹395 Cr₹1,105 Cr₹370 Cr₹413 Cr₹437 Cr₹571 Cr
Net Profit₹282 Cr₹295 Cr₹290 Cr₹699 Cr₹269 Cr₹302 Cr₹308 Cr₹420 Cr
EPS42.4
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹4,086 Cr₹6,496 Cr₹7,834 Cr₹8,778 Cr₹10,661 Cr₹11,225 Cr
Total Liabilities₹440 Cr₹593 Cr₹676 Cr₹819 Cr₹1,937 Cr₹2,074 Cr
Equity₹3,646 Cr₹5,903 Cr₹7,158 Cr₹7,959 Cr₹8,724 Cr₹9,151 Cr
Total Debt
Cash Flow
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹945 Cr₹916 Cr₹1,197 Cr₹675 Cr₹1,303 Cr₹1,269 Cr
Investing₹-766 Cr₹-1,524 Cr₹-1,003 Cr₹1,208 Cr₹-1,757 Cr₹1,705 Cr
Financing₹-7 Cr₹1,238 Cr₹35 Cr₹15 Cr₹-799 Cr₹-433 Cr
Free Cash Flow₹945 Cr₹916 Cr₹1,197 Cr₹675 Cr₹1,303 Cr₹1,269 Cr
Shareholding
Promoter 51.77% Institutions 39.18% Public 9.05%
Efficiency & Working Capital
ROCE15.8%
Interest Coverage26.3
Dividend Payout
Debtor Days99 d
Inventory Days110 d
Payable Days53 d
Cash Conversion Cycle155 d
Working Capital Days208 d
Shareholding Details

As of 2026-06-30

Promoter51.8%
FII8.7%
DII30.4%
Institutions39.2%
Public9.1%
Promoter Pledge0%
No. of Shareholders1,08,266
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters57.9%57.9%57.9%51.8%51.8%51.8%51.8%51.8%51.8%51.8%51.8%51.8%
FIIs4.9%4%3.6%6.9%4.5%5%6.9%7.4%7.9%7.6%7.3%8.7%
DIIs22.4%23.1%25.2%32.8%35.4%34.8%33.3%32.9%32.6%33%33.4%30.4%
Public14.8%15%13.3%8.5%8.3%8.3%8%7.9%7.6%7.6%7.5%9.1%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,15194,57891,5001,08,266
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Fosun Pharma Industrial Pte. LtdShareholding of Promoter and Promoter Group51.8%8.54 Cr
Hdfc Mutual Fund - Hdfc Mid-cap FundPublic Shareholding6.1%1.01 Cr
Mirae Asset Large & Midcap FundPublic Shareholding5.7%93,78,765
Nippon Life India Trustee Ltd- A/c Nippon India Growth Mid Cap FundPublic Shareholding4.9%81,31,364
Sbi Large & Midcap FundPublic Shareholding3.3%54,84,673
Icici Prudential India Opportunities FundPublic Shareholding1.8%29,53,459
Dsp Small Cap FundPublic Shareholding1.6%26,76,014
Government Pension Fund GlobalPublic Shareholding1.3%22,14,227
Uti-flexi Cap FundPublic Shareholding1.2%20,17,866
Ample Up LimitedShareholding of Promoter and Promoter Group0%10
Fosun Industrial Co LimitedShareholding of Promoter and Promoter Group0%10
Lustrous Star LimitedShareholding of Promoter and Promoter Group0%10
Regal Gesture LimitedShareholding of Promoter and Promoter Group0%10
Board of Directors
NameDesignationYear
SRINIVAS SADUChairman / Executive Director / MD / CEO2025
UDO JAHANNES VETTERIndependent Non Exe. Director2025
ESSAJI GOOLAM VAHANVATIIndependent Non Exe. Director2025
Jia Ai (Allen) ZhangNon-Exec & Non-Independent Dir2025
Naina Lal KidwaiIndependent Non Exe. Director2025
Wenjie ZhangNon-Exec & Non-Independent Dir2025
Wei HuangNon-Exec & Non-Independent Dir2025
SAMPATH KUMAR PALLERLAMUDICS / Compliance Officer / Vice President2025
William Robert KellerAdditional Director2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr
Segments — Geography
RegionRevenueShare
USA₹2,128 Cr61.5%
India₹556 Cr16.1%
Europe₹151 Cr4.4%
Canada₹66 Cr1.9%
Australia₹16 Cr0.5%
Rest Of The World₹546 Cr15.8%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹1501616
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-11Dividend (20/- per share)Final
dividend2026-08-11₹20 (2000%)Final
forthcoming2026-08-10Board Meetings
dividend2025-08-14₹18 (1800%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202517,8910015017,906
20254040000404
20252,225001502,240
Insider / Designated-Person Trades

14 recent disclosure(s)

Jayatheerth AdvaniDisposal · 1,000
K RAGHURAMACHANDRA RAODisposal · 1,000
K RAGHURAMACHANDRA RAODisposal · 1,000
Jayatheerth AdvaniDisposal · 500
SREENIVASA RAO SURAGAMDisposal · 500
SREENIVASA RAO SURAGAMDisposal · 1,000
Substantial Acquisitions (SAST)

11 disclosure(s)

Market11/04/2025 · 4,00,020
Market24/06/2024 · 60,000
Market19/06/2024 · 99,00,000
Market27/05/2024 · 5,85,086
Market09/04/2024 · 33,75,525
Market09/04/2024 · 61,65,486
Company Information
Incorporated1978
ChairmanSRINIVAS SADU
AuditorDeloitte Haskins & Sells
Investor Email[email protected]
🌐 www.glandpharma.com

📍 Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search